Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
66 hedge funds and large institutions have $23.7M invested in Zynerba Pharmaceuticals, Inc in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 11 closing their positions.
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
12% more funds holding
Funds holding: 59 → 66 (+7)
2% less capital invested
Capital invested by funds: $24.3M → $23.7M (-$555K)
67% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $3.96M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$962K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$576K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$488K |
| 5 |
BlackRock
New York
|
+$461K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$744K |
| 2 |
Millennium Management
New York
|
-$542K |
| 3 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$502K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$493K |
| 5 |
Morgan Stanley
New York
|
-$398K |
ZYNE Hedge Fund Activity: Q3 2018 in Review
66 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2018, worth a combined $23.7M — down 2.3% from $24.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ZYNE positions and 11 closed out — a net gain of 7 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.6M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $744K sold.
- 66 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2018, up from 59 in Q2 2018.
- Funds reported $23.7M of Zynerba Pharmaceuticals, Inc stock for Q3 2018, down 2.3% quarter-over-quarter.
- 18 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2018 and 11 closed out, a net change of +7 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2018 was Susquehanna International Group, an estimated $1.6M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2018 was Marshall Wace North America, an estimated $744K sold.
Based on aggregated 13F filings for Q3 2018.